Pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22

From Wikipedia, the free encyclopedia

The Pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40mg) or atorvastatin (80mg) and a 10 day course of the antibiotic gatifloxacin or placebo. The participants enrolled at 349 sites across Australia, Europe, and North America between November 2000 and December 2001, and the study concluded that statin treatment for secondary prevention reduced coronary heart disease (CHD) events and that atorvastatin had a more marked effect than pravastatin. The study was published in The New England Journal of Medicine and reported at the American College of Cardiology Annual Scientific Session in 2004.[1][2][3]

See also[]

References[]

  1. ^ Myat, Aung; Gershlick, A. H.; Gershlick, Tony (2012). Landmark Papers in Cardiovascular Medicine. Oxford University Press. pp. 33–35. ISBN 978-0-19-959476-4.
  2. ^ Brookes, Linda (16 April 2004). "PROVE IT-TIMI 22: Pravastatin or Atorvastatin Evaluation and Infection Therapy -- Thrombolysis in Myocardial Infarction 22". Medscape. Retrieved 12 April 2020.{{cite web}}: CS1 maint: url-status (link)
  3. ^ Pearson, Thomas A. (2010). "5. Clinical trial evidence for treatment of dyslipidaemia in the prevention of cardiovascular disease". In Kwiterovich, Peter O. (ed.). The Johns Hopkins Textbook of Dyslipidemia. Philadelphia: Lippincott Williams & Wilkins. p. 62. ISBN 978-0-7817-8265-4.
Stub icon

This medical treatment–related article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""